Evidence map›Paper›PMID 29440887›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2018

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.

James F Donohue, Vamsi K Bollu, Donald E Stull, Lauren M Nelson, Valerie Sl Williams, Michael D Stensland, Nicola A Hanania

Open access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pulmonary Function Decline in Alpha-1 Antitrypsin Deficiency: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2026
    Pooled it
  2. Article
  3. Article
  4. A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis.Medical decision making : an international journal of the Society for Medical Decision Making · 2019
    Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

James F DonohueDepartment of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Vamsi K BolluWorldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ.
Donald E StullData Analytics and Design Strategy.
Lauren M NelsonPsychometrics, RTI Health Solutions, Research Triangle Park, NC.
Valerie Sl WilliamsPsychometrics, RTI Health Solutions, Research Triangle Park, NC.
Michael D StenslandAgile Outcomes Research, Inc., Rochester, MN.
Nicola A HananiaSection of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.
Baylor College of Medicine · USBristol-Myers Squibb (France) · FRUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Symptom severity is the largest factor in determining subjective health in COPD. Symptoms (eg, chronic cough, dyspnea) are associated with decreased health-related quality of life (HRQoL). We evaluated the impact of arformoterol on HRQoL in COPD patients, measured by St George's Respiratory Questionnaire (SGRQ). Post hoc growth mixture model (GMM) analysis examined symptom response profiles. Methods: We examined data from a randomized, double-blind, parallel-group, 12-month safety trial of twice-daily nebulized arformoterol 15 µg (n=420) versus placebo (n=421). COPD severity was assessed by Global Initiative for Chronic Obstructive Lung Disease (GOLD) status. GMM analysis identified previously unknown patient subgroups and examined the heterogeneity in response to SGRQ Symptoms scores. Results: SGRQ Total score improved by 4.24 points with arformoterol and 2.02 points with placebo ( Conclusion: In this study, arformoterol treatment significantly improved HRQoL reflected by SGRQ. For the analysis performed on these data, arformoterol may be particularly effective in improving lung function and reducing hospitalizations among patients who are unable to quit smoking or present with more severe symptoms.

Indexed as

Quality of LifeAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDouble-Blind MethodForced Expiratory VolumeFormoterol FumarateHumansLungPulmonary Disease, Chronic ObstructiveRecovery of FunctionSeverity of Illness IndexSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesVital CapacityAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsFormoterol Fumarategrowth mixture modelHRQoLlong-acting beta agonistSt George’s Respiratory Questionnaire

Identifiers

PMID29440887
PMCPMC5804733
OpenAlexW2792053788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.